OncRef

Clinical Trial: NCT02143466

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-10-21

Study Overview

Brief Summary

The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer

Official Title

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Conditions

Advanced Non Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Part A - AZD9291 in combination with AZD6094
  • Drug: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
  • Drug: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
  • Drug: Part A - AZD9291 in combination with intermittent selumetinib
  • Drug: Part A - AZD9291 in combination with MEDI4736
  • Drug: Part B - AZD9291 in combination with AZD6094
  • Drug: Part B - AZD9291 in combination with selumetinib
  • Drug: Part B - AZD9291 in combination with MEDI4736
  • Drug: Part C - AZD6094 monotherapy (Japan only)
  • Drug: Part C - AZD9291 in combination with AZD6094 (Japan only)
  • Drug: Part D - AZD9291 in combination with AZD6094

Other Study ID Numbers

  • D5160C00006
  • 2016-004752-29
  • 2016

Start Date (Actual)

2014-08-05

Primary Completion Date (Actual)

2020-03-04

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

344

Study Type

Interventional

Phase

Phase 1